• Small Molecules
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers

Press Releases

Explore our archive of official statements and announcements, covering financial results, important milestones, and various CSR initiatives.
Syngene Results Q4 FY25 and full-year FY25
23rd Apr, 2025
Syngene concludes the acquisition of Biologics Manufacturing Facility from Emergent BioSolutions Inc.
19th Mar, 2025
Syngene Acquires its First Manufacturing Facility in the US
10th Mar, 2025
India’s CRDMO sector growth potential at $22 - $25 Billion by 2035, driving global pharma innovation: BCG-IPSO Report
25th Feb, 2025
Syngene International announces Leadership changes
10th Feb, 2025
Syngene reports third quarter results
23rd Jan, 2025
Syngene International announces the winners of the Annual Science Quiz, ‘Synquizitive’ across Bangalore, Dakshin Kannada and Hyderabad
10th Dec, 2024
Syngene reports second quarter results
23rd Oct, 2024
Syngene achieves silver in EcoVadis ESG assessment
13th Aug, 2024
Syngene reports first quarter results FY25
24th Jul, 2024

To view or email, Please share your details view

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details